Our Take
Two mega-deals don't prove sustained momentum; they prove two acquirers found targets worth the price, which is not the same as sector-wide appetite returning.
Why it matters
Medtech M&A stalled in 2023 and 2024 as interest rates climbed and valuations compressed. If deal flow is genuinely recovering, it suggests either financing conditions have loosened or strategic buyers see bargains worth acting on. Either way, smaller medtech founders and private equity backers are watching to see if liquidity windows are reopening.
Do this week
Deal teams: benchmark your medtech company against recent Penumbra and Masimo acquisition multiples before your next financing round so you price the business correctly against current buyer appetite.
Boston Scientific and Danaher anchor a recovery
Medtech deal volumes and values are tracking above first-half 2025 levels, according to PwC analysis (per MedTech Dive report). The rebound is anchored by two outsized transactions: Boston Scientific's acquisition of Penumbra and Danaher's purchase of Masimo. These deals represent the largest M&A activity in the sector since 2024, when deal velocity dropped significantly from the prior decade.
The timing matters. Medtech M&A contracted sharply in 2023 and 2024 as rising interest rates made debt financing expensive and public equity markets repriced growth companies downward. The sector had not seen deal volumes return to pre-2022 levels. Penumbra and Masimo acquisitions suggest at least some strategic buyers are willing to deploy capital again at current valuations.
One quarter doesn't erase two years of drought
Two major deals in a single reporting period can signal market confidence, but they do not constitute a trend. Both Boston Scientific and Danaher are tier-one strategic acquirers with fortress balance sheets and proven integration track records. Their activity reflects their own capital allocation decisions, not necessarily broader willingness across the buyer universe to close medtech transactions.
The real test is whether mid-market and smaller medtech companies see deal flow improve, or whether activity remains concentrated among a handful of mega-cap buyers picking trophy assets. If the latter, founders and PE backers should expect continued competition for the few deals that do close, with multiples under pressure despite headline announcements of "momentum."
For debt markets specifically, rising rates have not yet reversed course durably enough to make leveraged medtech acquisitions cheap again. Strategic buyers relying on all-cash or mostly-equity offers have an advantage; sponsors relying on bank debt do not.
Track buyer appetite at your scale
If you are selling a medtech business or advising on one, separate the headline recovery from your own deal environment. Pull comparable transaction multiples from the Penumbra and Masimo deals (both public companies), but do not assume those multiples apply to your segment or stage. Mega-deal multiples often exceed mid-market multiples by 30 to 50 percent, especially in high-growth verticals like neuroendovascular (Penumbra's core market).
Watch for signals in the next two quarters. If deal count stays above 2024 levels but Penumbra and Masimo remain the only headline transactions, the market has not truly recovered. If a new wave of $500M to $2B deals closes, you have a genuine shift. Until then, assume financing conditions are still tight and price your ask accordingly.